Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 7, Pages 3870-3884Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c02053
Keywords
-
Categories
Funding
- National Institute on Drug Abuse [DA026795, DA041435, DA045020 DA009158, DA007215]
- Canadian Institutes of Health Research
- Crohn's and Colitis Canada Chair in Inflammatory Bowel Disease Research at the University of Calgary
Ask authors/readers for more resources
Novel cannabinergic probes have been developed to stabilize cannabinoid receptors through tight binding interactions, exhibiting high binding affinity and potent agonist activity. A key ligand, 27a, displays exceptional megagonist properties, acting centrally and peripherally, distinguishing it from previously reported megagonists.
We report the development of novel cannabinergic probes that can stabilize the cannabinoid receptors (CBRs) through tight binding interactions. Ligand design involves the introduction of select groups at a judiciously chosen position within the classical hexahydrocannabinol template (monofunctionalized probes). Such groups include the electrophilic isothiocyanato, the photoactivatable azido, and the polar cyano moieties. These groups can also be combined to produce bifunctionalized probes potentially capable of interacting at two distinct sites within the CBR-binding domains. These novel compounds display remarkably high binding affinities for CBRs and are exceptionally potent agonists. A key ligand (27a, AM11245) exhibits exceptionally high potency in both in vitro and in vivo assays and was designated as megagonist, a property attributed to its tight binding profile. By acting both centrally and peripherally, 27a distinguishes itself from our previously reported megagonist AM841, whose functions are restricted to the periphery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available